▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system found under Section 4.8 of the Summary of Product Characteristics.
This website is intended to provide information to a healthcare audience outside the US and UK. It contains information on Xagrid and Anagrelide, which is primarily based on the Summary of Product Characteristics (SmPC) as approved by the European Commission.This website is not intended to be used to report adverse events or product quality complaints. If you would to report an adverse event or product quality complaint, please contact us at email@example.com
© 2017 Shire. All rights reserved. Shire and the Shire logo are registered trademarks of Shire International Pharmaceutical Holdings Ireland Limited or its affiliates.